MA56783B1 - Procédé de préparation d'ivosidenib et d'un intermédiaire de celui-ci - Google Patents
Procédé de préparation d'ivosidenib et d'un intermédiaire de celui-ciInfo
- Publication number
- MA56783B1 MA56783B1 MA56783A MA56783A MA56783B1 MA 56783 B1 MA56783 B1 MA 56783B1 MA 56783 A MA56783 A MA 56783A MA 56783 A MA56783 A MA 56783A MA 56783 B1 MA56783 B1 MA 56783B1
- Authority
- MA
- Morocco
- Prior art keywords
- ivosidenib
- preparing
- synthesis
- preparation
- relates
- Prior art date
Links
- WIJZXSAJMHAVGX-DHLKQENFSA-N ivosidenib Chemical compound FC1=CN=CC(N([C@H](C(=O)NC2CC(F)(F)C2)C=2C(=CC=CC=2)Cl)C(=O)[C@H]2N(C(=O)CC2)C=2N=CC=C(C=2)C#N)=C1 WIJZXSAJMHAVGX-DHLKQENFSA-N 0.000 title abstract 2
- 229950010738 ivosidenib Drugs 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 2
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
La présente invention concerne un procédé de préparation d'un solvate éthanol cristallin sensiblement pur et diastéréomériquement pur du composé iia et son utilisation pour la synthétisation de l'ivosidenib.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962884480P | 2019-08-08 | 2019-08-08 | |
| PCT/US2020/045368 WO2021026436A1 (fr) | 2019-08-08 | 2020-08-07 | Procédé de préparation d'ivosidenib et d'un intermédiaire de celui-ci |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA56783B1 true MA56783B1 (fr) | 2023-10-31 |
Family
ID=74504162
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA56783A MA56783B1 (fr) | 2019-08-08 | 2020-08-07 | Procédé de préparation d'ivosidenib et d'un intermédiaire de celui-ci |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US12479824B2 (fr) |
| EP (1) | EP4010331B1 (fr) |
| JP (1) | JP7644747B2 (fr) |
| KR (1) | KR20220061971A (fr) |
| CN (1) | CN114555584B (fr) |
| AU (1) | AU2020327013B2 (fr) |
| BR (1) | BR112022002253A2 (fr) |
| CA (1) | CA3150028A1 (fr) |
| CL (1) | CL2022000310A1 (fr) |
| CO (1) | CO2022001991A2 (fr) |
| CR (1) | CR20220090A (fr) |
| DK (1) | DK4010331T3 (fr) |
| EC (1) | ECSP22016924A (fr) |
| ES (1) | ES2967909T3 (fr) |
| FI (1) | FI4010331T3 (fr) |
| GE (2) | GEAP202415882A (fr) |
| HR (1) | HRP20231618T1 (fr) |
| HU (1) | HUE064193T2 (fr) |
| IL (1) | IL290377B2 (fr) |
| LT (1) | LT4010331T (fr) |
| MA (1) | MA56783B1 (fr) |
| MD (1) | MD4010331T2 (fr) |
| MX (1) | MX2022001619A (fr) |
| MY (1) | MY207344A (fr) |
| PE (1) | PE20221761A1 (fr) |
| PH (1) | PH12022550266A1 (fr) |
| PL (1) | PL4010331T3 (fr) |
| PT (1) | PT4010331T (fr) |
| RS (1) | RS64934B1 (fr) |
| SI (1) | SI4010331T1 (fr) |
| SM (1) | SMT202300489T1 (fr) |
| TW (1) | TWI890687B (fr) |
| WO (1) | WO2021026436A1 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR133410A1 (es) | 2023-08-01 | 2025-09-24 | Servier Lab | Cocristal de un inhibidor de idh1, proceso de preparación del mismo, composiciones farmacéuticas del mismo, y métodos de tratamiento que implican el mismo |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR053992A1 (es) | 2004-12-22 | 2007-05-30 | Astrazeneca Ab | Compuestos quimicos con actividad anticancerosa, un procedimiento para su preparacion, su uso en la preparacion de medicamentos y composicion farmaceutica. |
| EP1979348B1 (fr) | 2005-12-21 | 2012-01-18 | Abbott Laboratories | Composes antiviraux |
| US9474779B2 (en) | 2012-01-19 | 2016-10-25 | Agios Pharmaceuticals, Inc. | Therapeutically active compositions and their methods of use |
| KR20240010105A (ko) | 2014-03-14 | 2024-01-23 | 아지오스 파마슈티컬스 아이엔씨. | 치료적으로 활성인 화합물의 약제학적 조성물 |
| EP3202766B1 (fr) | 2014-10-01 | 2019-12-25 | Daiichi Sankyo Company, Limited | Dérivé d'isoxazole comme inhibiteur de l'isocitrate déshydrogénase 1 muté |
| WO2019104318A1 (fr) * | 2017-11-27 | 2019-05-31 | Teva Pharmaceuticals Usa, Inc. | Formes à l'état solide d'ivosidénib |
| MX2021000068A (es) | 2018-07-06 | 2021-03-25 | Agios Pharmaceuticals Inc | Formas y composiciones farmaceuticas de ivosidenib. |
| WO2020127887A1 (fr) | 2018-12-21 | 2020-06-25 | Sandoz Ag | Procédé de préparation d'un produit intermédiaire d'ivosidénib |
-
2020
- 2020-08-07 PT PT207584095T patent/PT4010331T/pt unknown
- 2020-08-07 CA CA3150028A patent/CA3150028A1/fr active Pending
- 2020-08-07 KR KR1020227007851A patent/KR20220061971A/ko active Pending
- 2020-08-07 RS RS20231183A patent/RS64934B1/sr unknown
- 2020-08-07 HU HUE20758409A patent/HUE064193T2/hu unknown
- 2020-08-07 SI SI202030329T patent/SI4010331T1/sl unknown
- 2020-08-07 MY MYPI2022000677A patent/MY207344A/en unknown
- 2020-08-07 MX MX2022001619A patent/MX2022001619A/es unknown
- 2020-08-07 CN CN202080070672.3A patent/CN114555584B/zh active Active
- 2020-08-07 HR HRP20231618TT patent/HRP20231618T1/hr unknown
- 2020-08-07 GE GEAP202415882A patent/GEAP202415882A/en unknown
- 2020-08-07 TW TW109126862A patent/TWI890687B/zh active
- 2020-08-07 CR CR20220090A patent/CR20220090A/es unknown
- 2020-08-07 PL PL20758409.5T patent/PL4010331T3/pl unknown
- 2020-08-07 LT LTEPPCT/US2020/045368T patent/LT4010331T/lt unknown
- 2020-08-07 US US17/634,524 patent/US12479824B2/en active Active
- 2020-08-07 IL IL290377A patent/IL290377B2/en unknown
- 2020-08-07 BR BR112022002253A patent/BR112022002253A2/pt unknown
- 2020-08-07 DK DK20758409.5T patent/DK4010331T3/da active
- 2020-08-07 FI FIEP20758409.5T patent/FI4010331T3/fi active
- 2020-08-07 PH PH1/2022/550266A patent/PH12022550266A1/en unknown
- 2020-08-07 MA MA56783A patent/MA56783B1/fr unknown
- 2020-08-07 AU AU2020327013A patent/AU2020327013B2/en active Active
- 2020-08-07 GE GEAP202015882A patent/GEP20247709B/en unknown
- 2020-08-07 JP JP2022507572A patent/JP7644747B2/ja active Active
- 2020-08-07 SM SM20230489T patent/SMT202300489T1/it unknown
- 2020-08-07 WO PCT/US2020/045368 patent/WO2021026436A1/fr not_active Ceased
- 2020-08-07 MD MDE20220658T patent/MD4010331T2/ro unknown
- 2020-08-07 PE PE2022000203A patent/PE20221761A1/es unknown
- 2020-08-07 EP EP20758409.5A patent/EP4010331B1/fr active Active
- 2020-08-07 ES ES20758409T patent/ES2967909T3/es active Active
-
2022
- 2022-02-07 CL CL2022000310A patent/CL2022000310A1/es unknown
- 2022-02-24 CO CONC2022/0001991A patent/CO2022001991A2/es unknown
- 2022-03-07 EC ECSENADI202216924A patent/ECSP22016924A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR3087439B1 (fr) | Procédé pour la préparation de 3α-hydroxy-5α-prégnan-20-one (brexanolone) | |
| AR043940A1 (es) | Inhibidores de sulfonamidas heterociclicas que contienen fluor- y trifluoralquilo de la produccion de beta amiloides y derivados de los mismos | |
| MA56508B1 (fr) | Inhibiteur de l'egfr pour le traitement du cancer | |
| CO6531444A2 (es) | Métodos sintéticos para compuestos espiro-oxoindol | |
| MX2021000348A (es) | 2-fluoro-3-nitrotolueno cristalino y procedimiento para la preparacion del mismo. | |
| ZA202201503B (en) | Urea compound for antagonizing lpa1 receptor | |
| CO6290666A2 (es) | Antagonistas del receptor de nmda para neuroproteccion | |
| ZA202305622B (en) | Free base crystalline form of a complement component c5a receptor | |
| MA40895B1 (fr) | Synthèse de copanlisib et son sel de dichlorhydrate | |
| MX2021007258A (es) | Composiciones de esparsentan amorfas. | |
| MA56783B1 (fr) | Procédé de préparation d'ivosidenib et d'un intermédiaire de celui-ci | |
| NO20054669L (no) | Substituerte kinobenzoxazinanaloger | |
| CA3242297A1 (fr) | Procede de preparation de derives de benzimidazole | |
| MX2023004102A (es) | Derivado de gamma-carbolina fusionado sustituido con heterociclo, metodo de preparacion del mismo, intermediarios del mismo y uso del mismo. | |
| CO2022007808A2 (es) | Polimorfos del compuesto antifúngico de triazol pc945 | |
| MX2023007429A (es) | Uso como agonista selectivo de receptor de melanocortina-4. | |
| SA520412408B1 (ar) | عملية تحضير مركبات ثنائي أريل أوكسي بنزو ديازول غير متجانسة مزدوجة الاستبدال | |
| MA58104B1 (fr) | Procédé et intermédiaire pour la préparation d'oxétane-2-ylméthanamine | |
| WO2020102053A8 (fr) | Procédés de préparation de dérivés de benzodiazépine cytotoxiques | |
| MX2025000464A (es) | Forma cristalina de un esteroide neuroactivo | |
| PH12021551794A1 (en) | Polymorphic forms of a substituted-quinoxaline-type bridged-piperidine compound | |
| PH12021550248A1 (en) | Borate of azetidine derivative | |
| MX2023010044A (es) | Compuesto para el tratamiento de trastornos cognitivos. | |
| MX2021012690A (es) | Formas cristalinas y metodos para producir formas cristalinas de un compuesto. | |
| MX2023011482A (es) | Proceso para preparar compuestos de cetona biciclicos. |